Overview

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-30

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the efficacy of Entinostat combined with Fulvestrant in HR+/HER2- advanced breast cancer patients with recurrence/progression after endocrine therapy (primary endpoint: progression-free survival \[PFS\]), and explore the correlation between peripheral blood mononuclear cell (PBMC) acetylation levels and treatment response to determine the baseline acetylation threshold .

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

entinostat
Fulvestrant